Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia

American Journal of Cardiology

Volumn 85, Issue 2, 2000, Pages 178-183

  Kajinami, Kouji ^a   Koizumi, Junji ^a   Ueda, Kosei ^b   Miyamoto, Susumu ^c   Takegoshi, Tadayoshi ^d   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Komatsu Municipal Hospital   (Japan)

^c Himi Municipal Hospital   (Japan)

^d Department of Internal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BENIDIPINE; CHOLESTEROL; DILTIAZEM; DISOPYRAMIDE; FUROSEMIDE; GLIBENCLAMIDE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEXILETINE; NICORANDIL; NISOLDIPINE; PITAVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL; WARFARIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; QUINOLINES;

EID: 0033984189     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00656-6     Document Type: Article

References (20)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1992;1569-1582.
2. Goldstein J.L., Brown M.S., Hobbs H.H. Familial hypercholesterolemia. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. 1995;1981-2030 McGraw Hill, New York.
3. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 89:1994;1333-1445.
4. Pyörölä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension . Atherosclerosis. 110:1994;121-161.
5. Guideline for Diagnosis and Treatment of Hyperlipidemia in Adults. J Jpn Atheroscler Soc. 25:1997;1-34. (in Japanese).
6. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors. Clin Pharmacokinet. 32:1997;403-425.
7. Aoki T., Nishimura H., Nakagawa S., Kojima J., Suzuki H., Tamaki T., Wada Y., Yokoo N., Sato F., Kimata H., Kitahara M., Toyoda K., Sakashita M., Saito Y. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsch/Drug Res. 47:1997;904-909.
8. Fujino H., Kojima J., Yamada Y., Kanda H., Kimata H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4) interspecies variation in laboratory animals and humans . Xeno Metab Disp. 14:1999;79-91.
9. Mabuchi H., Kamon N., Fujita H., Michishita I., Takeda M., Kajinami K., Itoh H., Wakasugi T., Takeda R. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Metabolism. 36:1987;475-479.
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma. Clin Chem. 18:1972;499-502.
11. Kajinami K., Mabuchi H., Koizumi J., Takeda R. Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin Chim Acta. 211:1992;93-99.
12. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
13. Marais A.D., Firth J.C., Bateman M.E., Byrnes P., Martens C., Mountney J. Atorvastatin an effective lipid-modifying agent in familial hypercholesterolemia . Arterioscler Thromb Vasc Biol. 17:1997;1527-1531.
14. Hoogerbrugge N. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolemia. J Intern Med. 244:1998;143-147.
15. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. High-dose of atorvastatin therapy in severe heterozygous familial hypercholesterolemia. Q J Med. 91:1998;291-294.
16. Arad Y., Ramakrishnan R., Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins implications for the pathophysiology of apoB production . J Lipid Res. 31:1990;567-582.
17. Mabuchi H., Tatami R., Ueda K., Ueda R., Haba T., Kametani T., Watanabe A., Wakasugi T., Ito S., Koizumi J., Ohta M., Miyamoto S., Takeda R. Serum lipid and lipoprotein levels in Japanese patients with familial hypercholesterolemia. Atherosclerosis. 32:1979;435-444.
18. Tatami R., Mabuchi H., Ueda K., Ueda R., Haba T., Kametani T., Ito S., Koizumi J., Ohta M., Miyamoto S., Nakayama A., Kanaya H., Oiwake H., Genda A., Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 64:1981;1174-1184.
19. Siedlik P.H., Olson S.C., Yang B.B., Stern R.H. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 39:1999;501-504.
20. Kantola T., Kivisto K.T., Neuvonen P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 64:1998;58-65.